Remedy Plan Therapeutics, a Gaithersburg, MD-based clinical-stage pharmaceutical company developing new, hyperbolic NAMPT inhibitors, raised $18M in funding.
Backers included Schooner Capital, Alexandria Venture Investments, and other existing investors.
The company intends to use the funds to accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase 1/2 trial in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS)
Led by CEO and Founder Greg Crimmins, Remedy Plan Therapeutics is a privately-held, clinical-stage pharmaceutical company developing new, hyperbolic NAMPT inhibitors. It is dysregulated in more than 20 diseases spanning oncology, autoimmunity, and metabolic disorders. Previous efforts by others to inhibit NAMPT activity resulted in severe on-target toxicities in healthy tissues, which prevented meaningful clinical activity.
It has developed an approach to NAMPT inhibition that never fully turns NAMPT activity off. This selectively avoids on-target toxicity in healthy tissues while still meaningfully inhibiting NAMPT activity in diseased cells.
FinSMEs
13/05/2025